Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book

A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers. The Orange Book, which lists FDA-approved drugs along with associated patents, serves to notify generic drug manufacturers of existing intellectual property rights. However, the FTC expressed […] Source